Skip to main content

Table 4 Multivariate modeling

From: Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment

 

Dyslipidemia During the 24-Month Follow-up Period

Index Regimen with High Weight Gain Risk vs Low/No Risk

Commercial

Medicaid

Commercial

Medicaid

Predictor (baseline characteristics)

Odds Ratio

P-value

Odds Ratio

P-value

Odds Ratio

P-value

Odds Ratio

P-value

 Intercept

0.02

 < 0.01

0.03

 < 0.01

3.52

 < 0.01

2.92

 < 0.01

 Age

1.05

 < 0.01

1.04

 < 0.01

0.99

 < 0.01

0.99

 < 0.01

 Female versus male

0.63

 < 0.01

1.08

0.26

0.92

0.39

0.88

 < 0.01

 Race: non-white versus whitea

-

-

0.84

0.03

-

-

-

-

 Race: Black vs. Whitea

-

-

-

-

-

-

0.95

0.43

 Race: Hispanic vs. Whitea

-

-

-

-

-

-

0.90

0.58

 Race: Other/Unknown vs. Whitea

-

-

-

-

-

-

1.14

0.13

 Charlson Comorbidity Index

-

-

-

-

0.99

0.89

1.04

0.05

 Weight gain/obesity

1.07

0.81

1.43

 < 0.01

0.75

0.11

0.88

0.09

 Dyslipidemia

-

-

-

-

1.01

0.94

0.92

0.28

 Pre-diabetes

-

-

-

-

1.16

0.61

1.07

0.64

 Type 2 diabetes mellitus

1.83

 < 0.01

2.24

 < 0.01

0.93

0.72

0.84

0.08

 Hypertension

1.19

0.27

1.46

 < 0.01

1.06

0.67

1.00

0.99

 Cardiovascular disease/events

1.52

0.02

1.26

0.03

1.04

0.79

1.06

0.46

 Cerebrovascular disease/events

-

-

-

-

0.69

0.14

0.91

0.49

Obstructive sleep apnea

-

-

-

-

1.57

0.06

0.77

0.07

 Involuntary movements

-

-

-

-

1.27

0.36

0.98

0.87

 Seizures/convulsions

-

-

-

-

1.04

0.86

0.86

0.20

 Sedation/somnolence

-

-

-

-

1.78

0.06

1.39

0.06

 Suicide ideation or behavior

1.36

0.23

1.01

0.95

1.24

0.22

1.00

0.98

 Paranoid schizophrenia

0.77

0.05

0.87

0.05

0.87

0.13

0.95

0.31

 Disorganized schizophrenia

-

-

-

-

1.23

0.49

0.97

0.81

 Other schizophrenia

0.80

0.11

0.81

 < 0.01

0.78

0.01

1.03

0.54

 Schizoaffective disorder

0.91

0.65

0.96

0.67

0.97

0.81

0.99

0.83

 Generalized anxiety disorder

-

-

-

-

1.35

0.13

0.89

0.39

 Other anxiety disorder

1.20

0.31

1.14

0.18

1.13

0.31

1.12

0.13

 Major depressive disorder

1.10

0.58

1.38

 < 0.01

0.82

0.09

1.22

0.01

 Bipolar disorder

0.74

0.29

1.31

0.06

1.32

0.13

1.06

0.55

 Other mood disorder

1.32

0.19

0.90

0.41

0.87

0.33

1.06

0.49

 Conduct disorder

-

-

-

-

1.37

0.18

1.04

0.76

 Disruptive behavior disorder

-

-

-

-

1.24

0.33

1.09

0.52

 Drug abuse

0.65

0.08

0.71

 < 0.01

1.43

 < 0.01

1.21

 < 0.01

 Alcohol abuse

1.11

0.73

0.97

0.81

1.17

0.42

0.99

0.89

 Other substance abuse/dependency

0.75

0.20

0.91

0.22

0.97

0.81

0.95

0.35

 Delusional disorders

-

-

-

-

1.71

 < 0.01

1.16

0.22

 SSRI medication

-

-

-

-

0.98

0.87

1.07

0.26

 SNRI medication

-

-

-

-

1.01

0.97

0.88

0.33

 Anti-anxiety prescription

-

-

-

-

0.91

0.39

0.93

0.26

 Anticonvulsant medication

-

-

-

-

0.98

0.86

1.20

 < 0.01

 Antihypertension medication

-

-

-

-

0.97

0.83

0.95

0.48

 Antidiabetic medication

-

-

-

-

0.77

0.23

0.76

0.02

 Lipid-lowering medication

-

-

-

-

1.21

0.21

1.21

0.03

 HWGR versus low or no risk

1.13

0.40

0.89

0.10

-

-

-

-

 MPR

1.75

 < 0.01

2.58

 < 0.01

-

-

-

-

 LAI antipsychotic in index regimen

1.04

0.86

0.83

0.04

-

-

-

-

  1. aRace/ethnicity data available for Medicaid sample only
  2. Abbreviations: HWGR High weight gain risk index treatment regimen, LAI Long-acting injectable, MPR Medication Possession Ratio, SNRI Serotonin and noradrenaline reuptake inhibitor, SSRI Selective serotonin reuptake inhibitor
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us